Third Rock Launches Nurix With Ambitions Of Next-Gen Velcade
This article was originally published in The Pink Sheet Daily
The recently uncovered biotech a la Third Rock and The Column Group is focused on the ubiquitin protease pathway and its applications in oncology.
You may also be interested in...
Nurix’s $120m Venture Round Will Bring Two Protein-Modulating Therapies To Clinic
Company’s technology harnesses E3 ligases to either degrade dysregulated proteins or inhibit a specific ligase to increase substrate protein levels for therapeutic benefit.
Gilead Dives Into Protein Degradation With Nurix Pact
Gilead is elbowing its way into the protein degradation field, seeking to build out a pipeline of oncology drugs in a $45m deal with Nurix. The pool is becoming crowded though, as many other big firms have latched onto this burgeoning field of R&D.
Celgene Returns To Forma’s Door, This Time With Option To Buy
The big biotech signed an expansive collaboration with the drug discovery company spanning multiple targets and numerous therapeutic areas. Celgene agreed to pay $225 million upfront and could eventually buy the company.